The Resilience at Risk: Structural Vulnerabilities and Strategic Pathways in the Indian Pharmaceutical Supply Chain

INDIA'S ROLE IN THE GLOBAL PHARMACEUTICAL ECOSYSTEM

1.1. Strategic Global Position and Economic Footprint

The Indian pharmaceutical industry maintains a formidable presence in global healthcare, recognised globally as the "Pharmacy of the World".⁷ By production volume, India is ranked the world's third-largest pharmaceutical industry, and 14th in terms of production value.⁸ This immense scale allows India to supply over 20% of global generic exports and address approximately 60% of worldwide demand for vaccines, serving as a critical global healthcare provider.³

The industry's economic footprint is substantial and heavily oriented toward international markets. For the fiscal year (FY) 2023–24, the total pharmaceutical market was valued at USD 50 billion. Notably, export value stood at USD 26.5 billion, marginally exceeding domestic consumption, which was valued at USD 23.5 billion.⁸ This export-driven model means that the economic stability and revenue growth of the sector are directly tied to adherence to stringent international regulatory standards. Any failure in quality or compliance translates immediately into a direct financial threat to national revenue and compromises India’s reputation among global buyers such as the US and the EU.⁹ The future trajectory is one of aggressive expansion, with market value projected to reach $120–$130 billion by 2030 and potentially $450 billion by 2047. This growth is contingent on expanding capabilities in complex, high-value modalities such as biosimilars and biologics, which necessitates significant supply chain maturation.¹

1.2. The Structure and Regulatory Architecture of the Indian PSC

The pharmaceutical supply chain (PSC) in India is a highly integrated yet complex network encompassing all phases, from research and development (R&D) and sourcing to manufacturing, quality control (QC), warehousing, distribution, and reverse logistics.¹¹ The system involves a diverse range of stakeholders, from large multinational generic manufacturers focused on exports to thousands of smaller domestic producers, often categorised as Micro, Small, and Medium Enterprises (MSMEs). .⁴

The regulatory framework is primarily governed by the Drugs and Cosmetics Act of 1940, which mandates that medications must be safe, effective, and of high quality.¹³ Enforcement is carried out by the Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller General of India (DCGI), which oversee import, manufacture, distribution, and sale.¹³ Crucially, the National Pharmaceutical Pricing Authority (NPPA) regulates drug costs, a function vital for maintaining affordability and domestic healthcare access.¹³ The necessity of continuous adherence to international quality and compliance requirements is heightened by the industry's deep reliance on export markets, making logistical and regulatory diligence a core business continuity function rather than a mere compliance exercise.

2. STRUCTURAL VULNERABILITIES: API DEPENDENCY AND POLICY RESPONSE

2.1. The Critical Threat of Single-Source Reliance

The most significant structural vulnerability facing the Indian PSC is its overwhelming reliance on imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs).¹⁵ This dependency exposes the industry to severe geopolitical and economic shocks. India is estimated to import between 70% and 80% of its total API requirements.¹⁶ This reliance is concentrated overwhelmingly in a single geography: China. In FY 2023–24, imports from China accounted for 71.72% of the overall bulk drug and intermediates imports by value and approximately 76% by volume.² Data reveals that for 45 critical APIs, India’s import dependency on China is 100%.¹⁵ This includes compounds manufactured through complex fermentation processes, a technological area where India has historically surrendered domestic production capacity ¹⁵

This single-source dominance creates substantial fragility. Geopolitical tensions or trade restrictions, like those observed during the COVID-19 pandemic, can immediately disrupt supply chains, causing manufacturing delays, medicine shortages, and instability in global markets.¹⁷ Furthermore, China’s near-monopoly grants it significant pricing power, leading to cost volatility and higher raw material expenses, which subsequently cut into the profit margins of Indian finished-drug exporters, thus diminishing their global competitiveness.¹⁷ This dependence also complicates India's strategic alignment with economic blocs such as the Quad (US, India, Australia, Japan) and the Indo-Pacific Economic Framework (IPEF), which seek secure and diversified supply chains. Current US import rules, for example, treat the API source as the drug’s country of origin, meaning an Indian-manufactured drug using a Chinese API may be subjected to Chinese tariff rates, limiting India's potential role as a trusted manufacturing alternative.¹⁸

2.2. Policy Initiatives for Self-Reliance (Aatmanirbhar Bharat)

To counteract this critical dependence, the Indian government launched significant policy interventions aimed at achieving self-reliance (Aatmanirbhar Bharat). .¹⁹

The primary tool has been the Production Linked Incentive (PLI) Scheme for KSMs, Drug Intermediates, and APIs. The scheme targeted 53 critical bulk drugs with the objective of boosting domestic manufacturing capability.²⁰ Initial achievements under the scheme have been highly encouraging in terms of investment metrics. The actual realised investment had reached ?4,253.92 crore by December 2024, surpassing the initial commitment of ?3,938.57 crore.⁵ Overall, 48 projects were selected, and 34 projects have been commissioned for 25 bulk drugs as of December 2024.^5. This successful attraction of capital has already resulted in import savings totalling ?1,362 crore.²²

However, there exists a critical divergence between successful investment realisation and measurable output impact. Despite the infusion of capital, the share of bulk drug imports from China actually increased from 68.02% in 2019-20 to 71.72% in 2023-24.^2. The establishment of large-scale chemical synthesis and fermentation units, particularly for complex APIs, requires significant lead time—often several years—to become fully operational, efficient, and cost-competitive.²³ In the interim, Chinese manufacturers continue to leverage their massive scale and historic financial support (such as tax incentives and low-cost loans) to maintain market dominance and suppress alternative suppliers.²³ This dynamic highlights that the PLI scheme is a long-term strategic endeavour, and short-term market resilience must be secured through complementary strategies to buffer against immediate shocks.

Complementing the PLI scheme, the government initiated the Scheme for Promotion of Bulk Drug Parks (BDPs), with a total budgetary outlay of ?3,000 crore ($350 million).²² Three parks have been approved in Gujarat, Himachal Pradesh, and Andhra Pradesh, designed to provide common infrastructure facilities.²² While conceptually sound, a structural challenge is immediately apparent: Indian parks risk insufficient operational scale compared to international counterparts. China’s special economic zones for pharmaceuticals are often 10 to 15 times the size of India’s parks, yielding greater operating efficiencies and lower overheads.²³ To achieve competitiveness, these BDP efforts require significant scaling and must be supported by centrally managed common infrastructure (e.g., common effluent treatment plants, uninterrupted energy supply, and improved road connectivity) provided in advance by the central government.²³ This specialised support is essential to ensure that the domestic manufacturing base can compete effectively on cost.

Table 2. Key Supply Chain Policy Interventions and Initial Performance (As of December 2024)

3. OPERATIONAL AND LOGISTICAL CHALLENGES

3.1. Infrastructure Gaps and High Logistics Overhead

Beyond raw material sourcing, the internal distribution and logistics networks introduce significant friction, translating into elevated operating costs. India’s overall logistics and warehousing costs are approximately 15% higher compared to developed economies, creating a persistent drag on the sector’s global competitiveness.⁷ The root cause is a highly fragmented system characterised by inadequate and non-standardised infrastructure, particularly in warehousing and cold storage, coupled with unreliable transportation networks.²⁴

3.2. The Cold Chain Imperative and Integrity Risks

The rapid growth in advanced medical products, including biosimilars, gene therapies, and biologics, has rendered a robust, precise temperature-controlled supply chain (cold chain) a necessity for the sector’s expansion.²⁶ However, the current cold chain infrastructure is structurally inadequate. The sector is highly fragmented, with over 3,500 players, and roughly 90% of the logistics sector is privately owned, lacking standardisation.³ Critically, only 8–10% of cold chain operators are compliant with World Health Organisation Good Distribution Practices (WHO-GDP) standards.³

These compliance failures have tangible economic and public health consequences. Nearly 20% of temperature-sensitive healthcare shipments reportedly arrive damaged or degraded due to insufficient infrastructure and transit disruptions.³ Globally, temperature excursions alone are estimated to cost the pharmaceutical industry approximately $15 billion annually.²⁹

Operational bottlenecks include frequent power supply disruptions due to India's reliance on coal, which compromise the integrity of temperature-controlled storage, particularly in industrial zones and smaller cities.²⁸ Furthermore, high freight rates, escalating fuel costs (higher than regional and global counterparts), and complex governmental and local bureaucratic processes impede efficient cold chain timelines.²⁸ Since the future of Indian pharma involves a paradigm shift from bulk shipping to precision delivery of high-value biologics and cell-and-gene therapies, the inability to securely manage the cold chain acts as a hard limit on the industry’s addressable market and its ability to realise the projected growth in the advanced modalities segment.⁷

3.3. Last-Mile Delivery Constraints and Rural Access

The integrity of the supply chain must extend to the last mile, especially in a country where more than 65% of the population resides in rural areas.³¹ Ensuring equitable access to essential medicines in these regions presents some of the most complex logistical hurdles. Conventional supply chains, which move medicines from large urban manufacturing hubs through city wholesalers to smaller rural distributors, are plagued by last-mile inefficiencies.³¹

Key challenges include inadequate road connectivity, limited transportation infrastructure in remote areas, and the high fixed costs associated with servicing widely dispersed populations.³¹ Innovative operational solutions are required to bridge this gap. Scholarly analyses suggest that utilising multimodal transport design and optimised vehicle routing (the vehicle routing problem approach) can effectively reduce high last-mile delivery costs in rural areas.³² Furthermore, exploring public transport and logistics integration models, where both passengers and freight are transported concurrently, offers a path to improving resource utilisation and enhancing last-mile distribution efficiency, drawing lessons from similar successful models implemented internationally ³²

4. REGULATORY COMPLIANCE AND QUALITY CONTROL HURDLES

4.1. The Good Manufacturing Practice (GMP) Reform and MSME Strain

In response to increased scrutiny from international regulatory bodies, the Central Drugs Standard Control Organisation (CDSCO) initiated mandatory implementation of revised Schedule M norms, enforcing WHO-Good Manufacturing Practice (GMP) compliant standards across all Indian pharmaceutical manufacturers.³³ This swift action underscores a governmental commitment to strengthening drug quality and rebuilding global trust.³³ Large manufacturers (sales turnover > ?250 crore) were given six months for compliance, while medium and small manufacturers were given one year.³³

However, this mandatory quality drive has created a significant strain on the vast ecosystem of Micro, Small, and Medium Enterprises (MSMEs). MSMEs are grappling with the high capital expenditure required for infrastructure upgrades, modernisation of machinery, and the implementation of sophisticated quality management systems.³⁴ Compounding this, new mandates, such as mandatory bio-equivalence studies for all generics, impose costs estimated at INR 250,000–500,000 per product, a financial burden that is disproportionately crippling for smaller units.³⁵

The immediate consequence of this policy acceleration is a risk of mass non-compliance and market disruption. As of May 2025, only 1,700 out of an estimated 6,000 MSME drug manufacturers had submitted upgrade plans, meaning over two-thirds had failed to take the necessary steps toward adherence.⁴ Failure to comply with the deadline carries the penalty of license suspension or cancellation.³³ The systemic risk inherent in this compliance gap is the potential for mass consolidation or closures, which could lead to widespread shortages of essential generic drugs, including oncology and cardiovascular medicines, impacting both domestic affordability and regional export competitiveness.⁴ This indicates a complex trade-off: securing global quality standards in the short term may jeopardise affordable domestic access. Policy intervention must therefore be strategically paired with financial support mechanisms to manage this transitional shock and maintain healthcare equity.

Recurring quality deficiencies cited in numerous inspections highlight the core problems that the Schedule M reforms seek to address. These often include failures in data integrity, such as the alleged deletion of failing test data or inadequate audit trails on electronic systems, as well as operational flaws like the absence of testing for raw materials before use, and faulty design of manufacturing and testing areas.³³

Table 4. Regulatory and Financial Pressures on Indian Pharmaceutical MSMEs

4.2. Counterfeit Medicines and Traceability Systems

The widespread circulation of counterfeit and substandard medicines poses a serious public health threat and severely damages India’s global reputation.³⁷ Domestic estimates suggest that 5% of medicines in India are counterfeit, while external reports claim that between 35% and 75% of counterfeit medicines supplied worldwide originate in India.³⁷

To combat this menace, the Indian government implemented the Drug Authentication and Verification Application (DAVA) system, based on global GS1 standards, mandating serialisation and unique identification codes for pharmaceutical exports.³⁹ This track and trace system provides real-time visibility and allows manufacturers and regulators to monitor product movement from production through distribution, enhancing product authentication.⁴¹ However, the rising prevalence of online pharmacies has complicated tracking efforts, providing illegal traders with a discreet platform to reach a broader audience.⁴¹ Furthermore, a lack of awareness among consumers about the risks associated with spurious products challenges the effective identification and reporting of suspicious items.⁴¹

5. THE WAY AHEAD: STRATEGIES FOR ENHANCED RESILIENCE AND EFFICIENCY

Achieving the projected industry valuation of $450 billion by 2047 requires strategic, scaled interventions that integrate policy incentives with advanced technology and infrastructure upgrades.¹ The path to resilience must address the core vulnerabilities of raw material dependence, logistical friction, and quality control deficits.

5.1. Focused Investment in Backwards Integration and Industrial Scaling

The Production Linked Incentive strategy must be refined to focus on high-barrier technologies. Given the continued dependence on China for fermentation-based products, future investment must strategically target the development of expertise and capacity in innovative chemistries, particularly fermentation and high-potency APIs.¹⁵ This requires integrating the speciality chemical industry with pharmaceutical quality standards and providing sustained PLI support.²³

Leveraging Foreign Direct Investment (FDI) inflows, which reached ?11,888 Crore in FY 2024–25 across pharmaceuticals and medical devices, is crucial for accelerating technology transfer and developing integrated, sophisticated domestic supply chains.⁵ Furthermore, the Bulk Drug Parks (BDPs) must achieve maximum operational efficiency. This entails ensuring comprehensive financial support from the central government for high-quality common facilities, such as effluent treatment plants and captive energy supplies, to guarantee operational efficiencies and cost competitiveness that can rival global manufacturing hubs.²³

5.2. Digital Transformation for Quality and Traceability

Digitalisation is the most immediate and effective mechanism for mitigating India's systemic regulatory and risk factors. Integrating advanced technologies offers a direct solution to quality control issues and counterfeiting.⁴²

Mandatory adoption of Blockchain technology and serialisation systems is critical for supply chain integrity. Case studies demonstrate the efficacy of Distributed Ledger Technology (DLT) in dramatically reducing fraud: implementation has been shown to reduce the prevalence of counterfeit medications from a baseline of 10–12% to 3–4% and simultaneously improve traceability from under 40% to over 85%.⁶ This technology provides immutable audit trails, directly addressing the endemic regulatory failing of poor data integrity observed in traditional manufacturing setups.³⁶

Artificial Intelligence (AI) must be leveraged to enhance planning and operational efficiency. AI-powered systems are vital for developing advanced demand forecasting models, which are critical for resilient risk management.⁴³ Reported efficacy of AI-driven forecasting shows enhanced demand precision from 70–75% to 85–90% and a corresponding minimisation of supply shortages by 60%.⁶ The shift toward mandatory, integrated digital systems (AI, Blockchain) represents a fundamental reorientation of quality control, moving from reactive, manual inspection to proactive, digitally-verified compliance, which is a prerequisite for sustained global market trust.

Table 3. Digital Technology Efficacy in Mitigating Key Supply Chain Risks